EPCA-2: a highly specific serum marker for prostate cancer.

摘要: OBJECTIVES: To describe the initial assessment of early prostate cancer antigen (EPCA)-2 as a serum marker for detection and to examine its sensitivity specificity. METHODS: Serum samples were obtained from 385 men: those with prostate-specific (PSA) levels less than 2.5 ng/mL, PSA ng/mL or greater negative biopsy findings, benign prostatic hyperplasia, organ-confined cancer, non-organ-confined disease, ng/mL. In addition, diverse group controls was assessed an enzyme-linked immunosorbent assay detect epitope EPCA-2 protein, EPCA-2.22. RESULTS: Using cutoff 30 EPCA-2.22 had 92% specificity (95% confidence interval 85% 96%) healthy men hyperplasia 94% [CI] 93% 99%) overall cancer. The in these selected groups patients 65% CI 55% 75%). Additionally, highly accurate differentiating between localized extracapsular disease (area under curve 0.89, 95% 0.82 0.97, P <0.0001) contrast 0.62, 0.50 0.75, = 0.05). CONCLUSIONS: results our study have shown that is novel biomarker associated has high accurately differentiates disease.